Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Biogerontology ; 14(3): 303-23, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23686362

ABSTRACT

During ageing skeletal muscles undergo a process of structural and functional remodelling that leads to sarcopenia, a syndrome characterized by loss of muscle mass and force and a major cause of physical frailty. To determine the causes of sarcopenia and identify potential targets for interventions aimed at mitigating ageing-dependent muscle wasting, we focussed on the main signalling pathway known to control protein turnover in skeletal muscle, consisting of the insulin-like growth factor 1 (IGF1), the kinase Akt and its downstream effectors, the mammalian target of rapamycin (mTOR) and the transcription factor FoxO. Expression analyses at the transcript and protein level, carried out on well-characterized cohorts of young, old sedentary and old active individuals and on mice aged 200, 500 and 800 days, revealed only modest age-related differences in this pathway. Our findings suggest that during ageing there is no downregulation of IGF1/Akt pathway and that sarcopenia is not due to FoxO activation and upregulation of the proteolytic systems. A potentially interesting result was the increased phosphorylation of the ribosomal protein S6, indicative of increased activation of mTOR complex1 (mTORC1), in aged mice. This result may provide the rationale why rapamycin treatment and caloric restriction promote longevity, since both interventions blunt activation of mTORC1; however, this change was not statistically significant in humans. Finally, genetic perturbation of these pathways in old mice aimed at promoting muscle hypertrophy via Akt overexpression or preventing muscle loss through inactivation of the ubiquitin ligase atrogin1 were found to paradoxically cause muscle pathology and reduce lifespan, suggesting that drastic activation of the IGF1-Akt pathway may be counterproductive, and that sarcopenia is accelerated, not delayed, when protein degradation pathways are impaired.


Subject(s)
Aging/physiology , Forkhead Transcription Factors/physiology , Insulin-Like Growth Factor I/physiology , Muscle, Skeletal/physiology , Proto-Oncogene Proteins c-akt/physiology , Signal Transduction/physiology , TOR Serine-Threonine Kinases/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Autophagy-Related Protein 7 , Female , Forkhead Box Protein O1 , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Knockout , Mice, Transgenic , Microtubule-Associated Proteins/genetics , Microtubule-Associated Proteins/physiology , Models, Animal , Muscle Proteins/genetics , Muscle Proteins/physiology , SKP Cullin F-Box Protein Ligases/genetics , SKP Cullin F-Box Protein Ligases/physiology , Sarcopenia/physiopathology , Serpin E2/genetics , Serpin E2/physiology , Tripartite Motif Proteins , Ubiquitin-Protein Ligases/genetics , Ubiquitin-Protein Ligases/physiology , Young Adult
2.
Parasitology ; 129(Pt 5): 613-26, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15552406

ABSTRACT

This paper describes the structure of the microfilarial reservoir of Loa loa in an endemic population of central Cameroon. The possible effects of age and sex on the prevalence and intensity of microfilaraemia have been explored. Logistic analysis showed that the prevalence of microfilaraemia increased significantly with age, reaching 60 % in the oldest males. This result suggests that the figure commonly reported, according to which only one third of the infected individuals were microfilaraemic, should be reconsidered; in addition, as part of surveys of loiasis, crude microfilaraemia prevalence values should be replaced by adjusted ones. The intensity of infection did not show any age-specific change. As a result, even if the oldest members of the male population are clearly the most at risk of developing post-ivermectin serious adverse reactions, especially Loa-encephalopathy, the other members of the population are not risk-free. Therefore, in those areas where the African Programme for Onchocerciasis Control is undertaking regular mass distributions of ivermectin for onchocerciasis control, and where loiasis is co-endemic, no subpopulation should be excluded from surveillance and monitoring during community directed treatments with ivermectin.


Subject(s)
Anthelmintics/therapeutic use , Disease Reservoirs , Ivermectin/therapeutic use , Loiasis/epidemiology , Adolescent , Adult , Age Distribution , Animals , Anthelmintics/adverse effects , Anthelmintics/pharmacology , Cameroon/epidemiology , Child , Child, Preschool , Endemic Diseases , Female , Humans , Ivermectin/adverse effects , Ivermectin/pharmacology , Loa/drug effects , Logistic Models , Loiasis/drug therapy , Loiasis/immunology , Male , Middle Aged , Nervous System Diseases/chemically induced , Onchocerciasis/drug therapy , Onchocerciasis/epidemiology , Onchocerciasis/prevention & control , Prevalence , Risk Factors , Sex Distribution
SELECTION OF CITATIONS
SEARCH DETAIL